Microbiome Therapeutics Market Poised for 23% CAGR Growth by 2030

NEW YORK - Oct. 3, 2024 - PRLog -- The microbiome therapeutics market was valued at $314.4 million in 2021 and is projected to reach $2,036.4 million by 2030, growing at a 23.1% CAGR from 2021 to 2030.

This growth is driven by the ability of gastrointestinal medications to address unmet therapeutic needs and limitations of conventional treatments. Additionally, factors like the expansion of the disease spectrum, rising strategic initiatives, and the presence of prominent players contribute to this rise.

Established biotech companies are strategically acquiring smaller firms focused on microbiome research to unlock new drug targets and treatments for multiple conditions. Furthermore, well-known companies are partnering in R&D collaborations to develop cost-effective therapies.

FMT as a Preferred Treatment

The fecal microbiota transplantation (FMT) segment generated significant revenue in the past year, anticipated to account for over 84% of the market share by 2030. This can be attributed to the growing usage of FMTs and their availability in capsule form, enhancing patient comfort, especially for treating C. difficile infection.

Oncology and autoimmune diseases also represent a notable portion of therapeutic demand. Microbial therapy's potential impact on digestive health is being studied for conditions such as melanoma and pancreatic cancer.

Gastrointestinal and infectious diseases are the primary targets for microbiome therapeutics, holding over 92% of the market share.

Browse detailed report on Microbiome Therapeutics Market Size, Share, Growth and Demand Forecast Report 2030 (https://www.psmarketresearch.com/market-analysis/microbio...)

North America Leads in Demand

North America is the leading region for microbiome therapeutics, with significant growth potential due to extensive healthcare R&D and a high cancer prevalence.

The U.S. dominates the North American market due to strong government support and increasing R&D in regenerative medicine. In the Asia-Pacific region, therapy demand is expected to grow at a 23% CAGR, driven by rising healthcare expenditures, increased clinical trials, and growing public awareness of microbial therapies.

Japan's healthcare system improvements are anticipated to boost demand for microbiome therapeutics. Similarly, Latin America and the Middle East & Africa are projected to witness rising adoption, driven by increased public and private healthcare funding focused on digestive health.